Deuterated compounds
US-2024270731-A1 · Aug 15, 2024 · US
Methods and pharmaceutical compositions for the treatment of myelodysplastic syndromes
US2017100378A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2017100378-A1 |
| Application number | US-201515316890-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 9, 2015 |
| Priority date | Jun 10, 2014 |
| Publication date | Apr 13, 2017 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
First claim
Opening claim text (preview).
1 . A method for treating a myelodysplastic syndrome in a subject in need thereof, comprising the step of administering to said subject an XPO1 inhibitor. 2 . A method for promoting or restoring erythrocyte maturation in a subject suffering from a myelodysplastic syndrome, comprising the step of administering to said subject an XPO1 inhibitor.
Assignees
Inventors
Classifications
specific for leukemia · CPC title
- A61K31/422Primary
not condensed and containing further heterocyclic rings · CPC title
having six-membered rings, e.g. delta-lactones · CPC title
Medicinal preparations containing organic active ingredients · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2017100378A1 cover?
- The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide met…
- Who is the assignee on this patent?
- Inserm (Institut Nat De La Santé Et De La Rech Médicale), Fond Imagine, Assist Publique-Hôpitaux De Paris (Aphp), and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/422. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Apr 13 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).